Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis

References

• Xydakis MS, Albers MW, Holbrook EH, Lyon DM, Shih RY, Frasnelli JA, Pagenstecher A, Kupke A, Enquist LW, Perlman S. Post-viral effects of COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021;20(9):1–11. doi:10.1016/s1474-4422(21)00182-4.
   PubMed Web of Science ®Google Scholar
• Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375(6578):267–269. doi:10.1126/science.abm2052.
   PubMed Web of Science ®Google Scholar
• Sansoè G, Aragno M, Wong F. COVID-19 and liver cirrhosis: focus on the nonclassical Renin-Angiotensin system and implications for therapy. Hepatology. 2021;74(2):1074–1080. doi:10.1002/hep.31728.
   PubMed Web of Science ®Google Scholar
• Thompson CK, Lee MK, Baker JL, Attai DJ, DiNome ML. Taking a second look at neoadjuvant endocrine therapy for the treatment of early stage estrogen receptor positive breast cancer during the COVID-19 outbreak. Ann Surg. 2020;272(2):e96–e7. doi:10.1097/sla.0000000000004027.
   PubMed Web of Science ®Google Scholar
• Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, Park J, Foox J, Hether T, Warren S, et al. The spatial landscape of lung pathology during COVID-19 progression. Nature. 2021;593(7860):564–569. doi:10.1038/s41586-021-03475-6.
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi:10.1158/2159-8290.Cd-20-0422.
   PubMed Web of Science ®Google Scholar
• Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and cancer consortium. Ann Oncol. 2021;32(6):787–800. doi:10.1016/j.annonc.2021.02.024.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020;10(10):1465–1474. doi:10.1158/2159-8290.Cd-20-0773.
   PubMed Web of Science ®Google Scholar
• Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893–903. doi:10.1016/s1470-2045(20)30309-0.
   PubMed Web of Science ®Google Scholar
• Shahidsales S, Aledavood SA, Joudi M, Molaie F, Esmaily H, Javadinia SA. COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Rep (Hoboken). 2021;4(5):e1378. doi:10.1002/cnr2.1378.
   PubMedGoogle Scholar
• Taghizadeh-Hesary F, Porouhan P, Soroosh D, PeyroShabany B, Shahidsales S, Keykhosravi B, Rahimi F, Houshyari M, Forouzanfar MM, Javadinia SA. COVID-19 in cancer and non-cancer patients. Int J Manage. 2021;14(4):e110907. doi:10.5812/ijcm.110907.
   Web of Science ®Google Scholar
• Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe COVID-19 pneumonia: pathogenesis and clinical management. Bmj. 2021;372:n436. doi:10.1136/bmj.n436.
   PubMed Web of Science ®Google Scholar
• Sidebottom DB, Gill D. Ronapreve for prophylaxis and treatment of COVID-19. BMJ. 2021;374:n2136. doi:10.1136/bmj.n2136.
   PubMedGoogle Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi:10.1056/NEJMoa2116044.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393. doi:10.1038/s41577-021-00542-x.
   PubMed Web of Science ®Google Scholar
• Young B, Tan TT, Leo YS. The place for remdesivir in COVID-19 treatment. Lancet Infect Dis. 2021;21(1):20–21. doi:10.1016/s1473-3099(20)30911-7.
   PubMed Web of Science ®Google Scholar
• Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, Metzendorf MI, Fischer AL, Kopp M, Stegemann M, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):Cd014963. doi:10.1002/14651858.Cd014963.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes AL, Lutrick K, et al. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–329. doi:10.1056/NEJMoa2107058.
   PubMed Web of Science ®Google Scholar
• Berlin DA, Gulick RM, Martinez FJ, Solomon CG. Severe Covid-19. N Engl J Med. 2020;383(25):2451–2460. doi:10.1056/NEJMcp2009575.
   PubMed Web of Science ®Google Scholar
• Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122–1127. doi:10.1126/science.abm8108.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Di Guardo A, Lagni A, Lotti V, Diani E, Navari M, Gibellini D. COVID-19 vaccine: between myth and truth. Vaccines (Basel). 2022;10(3):349. doi:10.3390/vaccines10030349.
   PubMed Web of Science ®Google Scholar
• Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):28. doi:10.1038/s41541-021-00292-w.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED,sJr., Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–1773. doi:10.1056/NEJMoa2110345.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. China’s COVID vaccines have been crucial - now immunity is waning. Nature. 2021;598(7881):398–399. doi:10.1038/d41586-021-02796-w.
   PubMed Web of Science ®Google Scholar
• Silveira MM, Moreira G, Mendonça M. DNA vaccines against COVID-19: perspectives and challenges. Life Sci. 2021;267:118919. doi:10.1016/j.lfs.2020.118919.
   PubMed Web of Science ®Google Scholar
• Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, Jaffee EM, Wherry EJ, Soria JC, D’Souza G. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 2021;11(2):233–236. doi:10.1158/2159-8290.Cd-20-1817.
   PubMed Web of Science ®Google Scholar
• Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, et al. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021;147:154–160. doi:10.1016/j.ejca.2021.01.033.
   PubMed Web of Science ®Google Scholar
• Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, et al. Efficacy of Covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi:10.1136/bmj-2021-068632.
   PubMedGoogle Scholar
• Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102(3a):2–9; discussion 25–6. doi:10.1016/s0002-9343(97)00003-x.
   PubMedGoogle Scholar
• Cederwall S, Påhlman LI. Respiratory adenovirus infections in immunocompetent and immunocompromised adult patients. Epidemiol Infect. 2020;147:e328. doi:10.1017/s0950268819002176.
   PubMed Web of Science ®Google Scholar
• Manuel O, Estabrook M. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13511. doi:10.1111/ctr.13511.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD.
   PubMed Web of Science ®Google Scholar
• Agbarya A, Sarel I, Ziv-Baran T, Agranat S, Schwartz O, Shai A, Nordheimer S, Fenig S, Shechtman Y, Kozlener E, et al. Efficacy of the mRNA-Based BNT162b2 COVID-19 vaccine in patients with solid malignancies treated with anti-neoplastic drugs. Cancers (Basel). 2021;13(16):4191. doi:10.3390/cancers13164191.
   PubMed Web of Science ®Google Scholar
• Amatu A, Pani A, Patelli G, Gagliardi OM, Loparco M, Piscazzi D, Cassingena A, Tosi F, Ghezzi S, Campisi D, et al. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. Eur J Cancer. 2022;163:16–25. doi:10.1016/j.ejca.2021.12.006.
   PubMed Web of Science ®Google Scholar
• Balcells ME, Le Corre N, Durán J, Ceballos ME, Vizcaya C, Mondaca S, Dib M, Rabagliati R, Sarmiento M, Burgos PI, et al. Reduced immune response to inactivated severe acute respiratory syndrome Coronavirus 2 vaccine in a cohort of immunocompromised patients in Chile. Clin Infect Dis. 2022;75(1):ciac167. doi:10.1093/cid/ciac167.
   PubMedGoogle Scholar
• Cavanna L, Citterio C, Biasini C, Madaro S, Bacchetta N, Lis A, Cremona G, Muroni M, Bernuzzi P, Lo Cascio G, et al. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy. Eur J Cancer. 2021;157:441–449. doi:10.1016/j.ejca.2021.08.035.
   PubMed Web of Science ®Google Scholar
• Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y, et al. Humoral responses after SARS-CoV-2 mRNA vaccination and breakthrough infection in cancer patients. Mayo Clin Proc Innov Qual Outcomes. 2022;6(2):120–125. doi:10.1016/j.mayocpiqo.2021.12.004.
   PubMedGoogle Scholar
• Cortés A, Casado JL, Longo F, Serrano JJ, Saavedra C, Velasco H, Martin A, Chamorro J, Rosero D, Fernández M, et al. Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. Eur J Cancer. 2022;166:229–239. doi:10.1016/j.ejca.2022.02.017.
   PubMed Web of Science ®Google Scholar
• Di Noia V, Pimpinelli F, Renna D, Barberi V, Maccallini MT, Gariazzo L, Pontone M, Monti A, Campo F, Taraborelli E, et al. Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution. Clin Cancer Res. 2021;27(24):6815–6823. doi:10.1158/1078-0432.Ccr-21-2439.
   PubMed Web of Science ®Google Scholar
• Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2(12):1321–1337. doi:10.1038/s43018-021-00274-w.
   Google Scholar
• Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, et al. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer. J Infect Chemother. 2022;28(4):516–520. doi:10.1016/j.jiac.2021.12.021.
   PubMed Web of Science ®Google Scholar
• Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A, et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(10):1507–1513. doi:10.1001/jamaoncol.2021.2675.
   PubMed Web of Science ®Google Scholar
• Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, et al. Efficacy of severe acute respiratory syndrome Coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. 2022;17(2):239–251. doi:10.1016/j.jtho.2021.10.015.
   PubMed Web of Science ®Google Scholar
• Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283. doi:10.1016/j.esmoop.2021;6(6):100283.
   PubMed Web of Science ®Google Scholar
• Haidar G, Agha M, Bilderback A, Lukanski A, Linstrum K, Troyan R, Rothenberger S, McMahon DK, Crandall MD, Sobolewksi MD, et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study. Clin Infect Dis. 2022;19(6):385–401. doi:10.1093/cid/ciac103.
   Google Scholar
• Iacono D, Cerbone L, Palombi L, Cavalieri E, Sperduti I, Cocchiara RA, Mariani B, Parisi G, Garufi C. Serological response to COVID-19 vaccination in patients with cancer older than 80 years. J Geriatr Oncol. 2021;12(8):1253–1255. doi:10.1016/j.jgo.2021.06.002.
   PubMed Web of Science ®Google Scholar
• Linardou H, Spanakis N, Koliou GA, Christopoulou A, Karageorgopoulou S, Alevra N, Vagionas A, Tsoukalas N, Sgourou S, Fountzilas E, et al. Responses to SARS-CoV-2 vaccination in patients with cancer (Recover study): a prospective cohort study of the hellenic cooperative oncology group. Cancers. 2021;13(18):4621. doi:10.3390/cancers13184621.
   PubMed Web of Science ®Google Scholar
• Liontos M, Terpos E, Markellos C, Zagouri F, Briasoulis A, Katsiana I, Skafida E, Fiste O, Kunadis E, Andrikopoulou A, et al. Immunological response to COVID-19 vaccination in ovarian cancer patients receiving PARP inhibitors. Vaccines (Basel). 2021;9(10):1148. doi:10.3390/vaccines9101148.
   PubMed Web of Science ®Google Scholar
• Margalit O, Shacham-Shmueli E, Itay A, Berger R, Halperin S, Jurkowicz M, Levin EG, Olmer L, Regev-Yochay G, Lustig Y, et al. Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours. Eur J Cancer. 2022;168:51–55. doi:10.1016/j.ejca.2022.03.013.
   PubMed Web of Science ®Google Scholar
• Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, Benouaich-Amiel A, Ben-Zvi H, Moskovits N, Brenner B, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133–1140. doi:10.1001/jamaoncol.2021.2155.
   PubMed Web of Science ®Google Scholar
• Massarweh A, Tschernichovsky R, Stemmer A, Benouaich-Amiel A, Siegal T, Eliakim-Raz N, Stemmer SM, Yust-Katz S. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. J Neurooncol. 2022;156(3):483–489. doi:10.1007/s11060-021-03911-7.
   PubMed Web of Science ®Google Scholar
• Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778. doi:10.1016/S1470-2045%2821%2900213-8.
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study. J Clin Oncol. 2022;40(1):12–23. doi:10.1200/jco.21.01891.
   PubMed Web of Science ®Google Scholar
• Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22(12):1681–1691. doi:10.1016/s1470-2045(21)00574-x.
   PubMed Web of Science ®Google Scholar
• Palaia I, Caruso G, Di Donato V, Vestri A, Napoli A, Perniola G, Casinelli M, Alunni Fegatelli D, Campagna R, Tomao F, et al. Pfizer-BioNtech COVID-19 vaccine in gynecologic oncology patients: a prospective cohort study. Vaccines (Basel). 2021;10(1):21. doi:10.3390/vaccines10010012.
   PubMed Web of Science ®Google Scholar
• Rahav G, Lustig Y, Lavee J, Ohad B, Magen H, Hod T, Noga S-T, Shmueli ES, Drorit M, Ben-Ari Z, et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: a prospective cohort study. EClinicalMedicine. 2021;41:101158. doi:10.1016/j.eclinm.2021.101158.
   PubMedGoogle Scholar
• Shmueli ES, Itay A, Margalit O, Berger R, Halperin S, Jurkowicz M, Levin EG, Levy I, Olmer L, Regev-Yochay G, et al. Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study. Eur J Cancer. 2021;157:124–131. doi:10.1016/j.ejca.2021.08.007.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, Peyton KL, Uhrlaub JL, Ripperger TJ, Jergović M, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27(11):2002–2011. doi:10.1038/s41591-021-01542-z.
   PubMed Web of Science ®Google Scholar
• Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081. doi:10.1016/j.ccell.2021.06.002.
   PubMed Web of Science ®Google Scholar
• Trontzas IP, Vathiotis I, Economidou C, Petridou I, Gomatou G, Grammoustianou M, Tsamis I, Syrigos N, Anagnostakis M, Fyta E, et al. Assessment of seroconversion after SARS-CoV-2 vaccination in patients with lung cancer. Vaccines (Basel). 2022;10(4):618. doi:10.3390/vaccines10040618.
   PubMed Web of Science ®Google Scholar
• Valanparambil R, Carlisle J, Linderman S, Akthar A, Millett RL, Lai L, Chang A, McCook A, Switchenko J, Nasti T, et al. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: reactivity to vaccine antigen and variants of concern. medRxiv. 2022. doi:10.1101/2022.01.03.22268599.
   PubMedGoogle Scholar
• Yasin AI, Aydin SG, Sumbul B, Koral L, Simsek M, Geredeli C, Ozturk A, Perkin P, Demirtas D, Erdemoglu E, et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022;18(10):1235–1244. doi:10.2217/fon-2021-1248.
   PubMed Web of Science ®Google Scholar
• Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, von Lilienfeld-Toal M. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385–401. doi:10.1038/s41571-022-00610-8.
   PubMed Web of Science ®Google Scholar
• Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Alessio N, Comolli G, Sarasini A, Sammartino JC, Ferrari A, et al. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study. ESMO Open. 2022;7(2):100458. doi:10.1016/j.esmoop.2022.100458.
   PubMed Web of Science ®Google Scholar
• Peeters M, Verbruggen L, Teuwen L, Vanhoutte G, Vande Kerckhove S, Peeters B, Raats S, Van der Massen I, De Keersmaecker S, Debie Y, et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open. 2021;6(5):100274. doi:10.1016/j.esmoop.2021.100274.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, Liau K, Lagkadinou E, Türeci Ö, Şahin U, et al. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine. 2022;40(10):1483–1492. doi:10.1016/j.vaccine.2021.12.046.
   PubMed Web of Science ®Google Scholar
• Shmueli ES, Lawrence YR, Rahav G, Itay A, Lustig Y, Halpern N, Boursi B, Margalit O. Serological response to a third booster dose of BNT162b2 COVID-19 vaccine among seronegative cancer patients. Cancer Rep (Hoboken). 2022;5(8):e1645. doi:10.1002/cnr2.1645.
   PubMedGoogle Scholar
• Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki H, Haji Ghadery A, Shabani M, Tabary M, Aryannejad A, SeyedAlinaghi S, Rezaei N. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):23. doi:10.1186/s40001-022-00648-5.
   PubMed Web of Science ®Google Scholar
• Urakawa R, Isomura ET, Matsunaga K, Kubota K, Ike M. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study. BMC Infect Dis. 2022;22(1):179. doi:10.1186/s12879-022-07175-y.
   PubMed Web of Science ®Google Scholar
• Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, Yap EPH, Martinez-Sobrido L, Torrrelles JB, Lippi G, et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNtech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;28:1–18. doi:10.1080/10408363.2022.2038539.
   Google Scholar
• Javadinia SA, Ariamanesh M, Nabavifard M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Hatami F, Ghasemi A, Lyman GH, Welsh JS, et al. Multicenter study of antibody seroprevalence against COVID-19 in patients presenting to iranian cancer centers after one year of the COVID-19 pandemic. Cancer Invest. 2022;40(2):115–123. doi:10.1080/07357907.2021.1995742.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, Nitido AD, et al. COVID-19-Neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–88.e11. doi:10.1016/j.cell.2020.12.015.
   PubMed Web of Science ®Google Scholar
• Roozendaal R, Solforosi L, Stieh DJ, Serroyen J, Straetemans R, Dari A, Boulton M, Wegmann F, Rosendahl Huber SK, van der Lubbe JEM, et al. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques. Nat Commun. 2021;12(1):5877. doi:10.1038/s41467-021-26117-x.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423–4428. doi:10.1016/j.vaccine.2021.05.063.
   PubMed Web of Science ®Google Scholar
• Vidal SJ, Collier AY, Yu J, McMahan K, Tostanoski LH, Ventura JD, Aid M, Peter L, Jacob-Dolan C, Anioke T, et al. Correlates of neutralization against SARS-CoV-2 variants of concern by early pandemic sera. J Virol. 2021;95(14):e0040421. doi:10.1128/jvi.00404-21.
   PubMed Web of Science ®Google Scholar
• Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021;6(1):48. doi:10.1038/s41392-021-00481-y.
   PubMed Web of Science ®Google Scholar
• Corti C, Crimini E, Tarantino P, Pravettoni G, Eggermont AMM, Delaloge S, Curigliano G. SARS-CoV-2 vaccines for cancer patients: a call to action. Eur J Cancer. 2021;148:316–327. doi:10.1016/j.ejca.2021.01.046.
   PubMed Web of Science ®Google Scholar
• Barrière J, Re D, Peyrade F, Carles M. Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer. Eur J Cancer. 2021;154:66–72. doi:10.1016/j.ejca.2021.06.008.
   PubMed Web of Science ®Google Scholar
• Mairhofer M, Kausche L, Kaltenbrunner S, Ghanem R, Stegemann M, Klein K, Pammer M, Rauscher I, Salzer HJF, Doppler S, et al. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer. Cancer Cell. 2021;39(9):1171–1172. doi:10.1016/j.ccell.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–484. doi:10.1038/s41577-021-00578-z.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063.
   PubMed Web of Science ®Google Scholar
• Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19. doi:10.1016/j.cell.2020.09.038.
   PubMed Web of Science ®Google Scholar
• Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, Zhuang Y, Tham CYL, Chia A, Smith GJD, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728. doi:10.1016/j.celrep.2021.108728.
   PubMed Web of Science ®Google Scholar
• Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021;27(7):1147–1148. doi:10.1038/s41591-021-01432-4.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, Zepeski A, et al. Sustained effectiveness of Pfizer-BioNtech and moderna vaccines against COVID-19 associated hospitalizations among adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1156–1162. doi:10.15585/mmwr.mm7034e2.
   PubMed Web of Science ®Google Scholar
• Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R, et al. Effectiveness of Pfizer-BioNtech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163–1166. doi:10.15585/mmwr.mm7034e3.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, Backenson B, Hoefer D, Morne J, Bauer U, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1150–1155. doi:10.15585/mmwr.mm7034e1.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, et al. Evaluation of antibody response to SARS-CoV-2 mRNA-1273 vaccination in patients with cancer in Florida. JAMA Oncol. 2022;8(5):748–754. doi:10.1001/jamaoncol.2022.0001.
   PubMed Web of Science ®Google Scholar
• Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, Hatami F, Fereidouni M, Welsh JS, Javadinia SA. Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest. 2022;40(1):26–34. doi:10.1080/07357907.2021.1992420.
   PubMed Web of Science ®Google Scholar
• Joudi M, Moradi Binabaj M, Porouhan P, PeyroShabany B, Tabasi M, Fazilat-Panah D, Khajeh M, Mehrabian A, Dehghani M, Welsh JS, et al. A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does Trastuzumab interfere with the outcome? Front Endocrinol (Lausanne). 2022;13:798975. doi:10.3389/fendo.2022.798975.
   PubMed Web of Science ®Google Scholar
• Javadinia SA, Alizadeh K, Mojadadi MS, Nikbakht F, Dashti F, Joudi M, Harati H, Welsh JS, Farahmand SA, Attarian F. COVID-19 vaccination in patients with malignancy; a systematic review and meta-analysis of the efficacy and safety. Front Endocrinol (Lausanne). 2022;13:860238. doi:10.3389/fendo.2022.860238.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383(16):1544–1555. doi:10.1056/NEJMoa2024671.
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–1520. doi:10.1016/s0140-6736(17)31665-3.
   PubMed Web of Science ®Google Scholar
• Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326–3334. doi:10.1016/j.vaccine.2019.04.074.
   PubMed Web of Science ®Google Scholar
• Fan YJ, Chan KH, Hung IF. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3. Vaccines (Basel). 2021;9(9):989. doi:10.3390/vaccines9090989.
   PubMed Web of Science ®Google Scholar